FHL2 antibody

Catalog No. ABIN265171

Product Details anti-FHL2 Antibody

Target: FHL2 (Four and A Half LIM Domains 2 (FHL2))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This FHL2 antibody is un-conjugated

Application: Western Blotting (WB)

Purification: Purified

Immunogen: Synthetic peptide derived from the human FHL2 protein

Isotype: IgG

Application Details

Application Notes: Western Blot: (0.5-2 μg/mL).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Buffer: Phosphate buffered saline with 0.08 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: -20 °C

Storage Comment: Store the product (in aliquots) at -20 °C. Can be shipped at 2 - 8 °C.

Target Details for FHL2

Target: FHL2 (Four and A Half LIM Domains 2 (FHL2))

Alternative Name: FHL2 / SLIM3 (FHL2 Products)

Synonyms: AAG11 antibody, DRAL antibody, FHL-2 antibody, SLIM-3 antibody, SLIM3 antibody, C76204 antibody, FHL2 antibody, zgc:92428 antibody, zgc:103466 antibody, four and a half LIM domains 2 antibody, four and a half LIM domains 2a antibody, four and a half LIM domains 2b antibody, FHL2 antibody, Fhl2 antibody, fhl2 antibody, fhl2a antibody, fhl2b antibody

Background: Sphingosine kinase-1 (SK1) is a key enzyme that catalyzes the phosphorylation of sphingosine to sphingosine-1-phosphate (S1P). SK1, and its product S1P, regulate numerous and diverse biological functions, including cell growth, differentiation, proliferation, and apoptosis. S1P also plays a central role in cardiac development and ischemic preconditioning. FHL2 (SLIM3) has been identified as a SK1-interacting protein in mammalian cardiomyocytes. FHL2, but not FHL1 or FHL3, interacts with SK1, and FHL2 colocalizes with SK1 in the cytoplasm of these cells. The interaction of FHL2 with SK-1 involves the C-terminal portion of SK1. Overexpression of FHL2 has been found to attneuate the activity and antiapoptotic effects of SK1. Endothelin-1, a potent survival factor in cardiomyocytes, inhibits FHL2-SK1 association and increases SK1 activity. FHL2 is therefore a novel inhibitor of SK1 activity in cardiomyocytes and targeting FHL2 may prevent myocardial apoptosis through activation of SK1. A transcriptional coactivator, FHL2 is also known to form complexes consisting of Proline-, glutamic acid-, and leucine-rich protein-1 (PELP1), FHL2, and androgen receptors (AR) in prostate cancer cells, perhaps functioning as a molecular adaptor with PELP1 in the progression of prostate cancer.Synonyms: DRAL, FHL-2, Four and a half LIM domains protein 2, LIM domain protein DRAL, SLIM 3, Skeletal muscle LIM-protein 3

Gene ID: 9606

UniProt: Q14192

Pathways: Intracellular Steroid Hormone Receptor Signaling Pathway, Regulation of Lipid Metabolism by PPARalpha